Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN versus ROLVEDON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN versus ROLVEDON.
ROBAXIN vs ROLVEDON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
ROLVEDON (eflapegrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) agonist. It binds to G-CSF receptors on neutrophil progenitors, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
5 mg subcutaneously once weekly.
None Documented
None Documented
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Approximately 20 hours in adults; prolonged in renal impairment, requiring dose adjustment
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Primarily renal; approximately 80% of the dose excreted unchanged in urine, with minor biliary/fecal elimination (<10%)
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant